Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 4Phase 1/2 1

Status

Withdrawn 2Terminated 2

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 16Plasma cell 11Other hematologic neoplasm 9Gastrointestinal 4CNS 4Sarcoma 3Dermatologic 3Myeloid 2Genitourinary 2Endocrine 2Breast 2Thoracic 1NET 1Head & Neck 1

Conditions

Glioma 2Glioblastoma 2Rhabdoid Tumor 1Recurrence 1Oligodendroglioma 1Gliosarcoma 1Diffuse Intrinsic Pontine Glioma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 258Radiotherapy 147Bevacizumab 142Etoposide 68Cyclophosphamide 68Carboplatin 66Magnetic Resonance Spectroscopy 58Irinotecan 53Cisplatin 52Vincristine 45Filgrastim 43pembrolizumab 40Radiosurgery 36Nivolumab 36Radiation 34Topotecan 31Doxorubicin 30Specimen Handling 29sargramostim 28Lomustine 27Erlotinib Hydrochloride 27Peripheral Blood Stem Cell Transplantation 25Carmustine 25Thiotepa 24Everolimus 23Chemotherapy, Adjuvant 23Surgical Procedures, Operative 22Isotretinoin 22Ipilimumab 22Melphalan 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Panobinostat × CNS × Clear all
NCT04897880 2025-02-24

NORTH

Australian & New Zealand Children's Haematology/Oncology Group

Phase 2 Terminated
25 enrolled
CNS

Brain Neoplasms, Rhabdoid Tumor

NCT03632317 2019-08-19

A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas

University of Michigan Rogel Cancer Center

Phase 2 Withdrawn
CNS

Diffuse Intrinsic Pontine Glioma, Glioma

NCT01115036 2013-06-19

CLBH589C

Duke University

Phase 2 Withdrawn
CNS

Glioblastoma, Recurrence

NCT00848523 2010-07-16

Study of LBH589 (Panobinostat) to Treat Malignant Brain Tumors

Neurological Surgery, P.C.

Phase 2 Terminated
6 enrolled
CNSSarcoma

Astrocytoma, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡